🇺🇸 FDA
Pipeline program

NBI-921352

NBI-921352-DEE2013

Phase 2 small_molecule active

Quick answer

NBI-921352 for SCN8A Developmental and Epileptic Encephalopathy Syndrome is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 2 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials